Research & Development
Read what the 2020 AMR Benchmark found when it analysed the R&D pipelines of eight large research-based companies and 13 pharmaceutical SMEs. It has mapped their medicine and vaccine projects targeting priority bacterial and fungal pathogens.
Read the results of the 2020 AMR Benchmark analysis into how eight large research-based companies and nine generic medicine manufacturers aim to minimise the risk that antibacterial discharge released from factories contributes to AMR.
Appropriate Access & Stewardship
Read the findings from the 2020 AMR Benchmark on access strategies for antibacterial and antifungal products in LMICs from eight large research-based companies and nine generic medicine manufacturers, as well as stewardship initiatives.